NCT03315468: RIC-Mel

French Clinical Datbase of Melanoma Patients (RIC-Mel)

Recruiting now Last updated 22 July 2025

What this trial tests

trial in Melanoma (Skin) in 16,000 participants. Currently enrolling.

Timeline

1 March 2012

Primary endpoint
1 March 2030

1 March 2030

Quick facts

Lead sponsor	Nantes University Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	16,000
Start date	1 March 2012
Primary completion	1 March 2030
Estimated completion	1 March 2030
Sites	1 location across France

Conditions studied

• Melanoma (Skin) — all drugs for Melanoma (Skin) →

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Melanoma (Skin). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With a high incidence, low survival rates and limiter availability of effective treatment, melanoma is one of the research priorities for health authorities. Optimizing the development of both academic and private research requires the availability information on the features of patients.

To meet this need, the French Multidisciplinary Melanoma Group (GMFMel) in collaboration with INCa (French National Cancer Institute), the CeNGEPS (National Centre for Healthcare Products Trial Management) and the CIC-BT0503 from Nantes University Hospital (Biotherapy Clinical Centre of Investigation) has set up in April 2011 a Clinical Investigation Network for melanoma, called the CeNGEPS-GMFMel network. Nowadays, the network is named :

RIC-Mel : network for Research and Clinical Investigation on Melanoma. Aims of the network are to promote translational and epidemiological projects as well as to optimize the achievements of clinical trials.

To achieve these goals, a database was launched in 2012 that gives a permanently updates mapping of melanoma treated in France with the key information needed for any research projects.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients.
   Roger A, Finet A, Boru B, Beauchet A, et al · · 2018 · cited 53× · PMID 30034949 · DOI 10.1080/2162402x.2018.1442166
2. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
   Bouchereau S, Chaplain L, Fort M, Beauchet A, et al · · 2021 · cited 19× · PMID 34262147 · DOI 10.1038/s41416-021-01486-8
3. Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients.
   Saint-Jean M, Fronteau C, Peuvrel L, Khammari A, et al · · 2020 · cited 14× · PMID 32702928 · DOI 10.1097/md.0000000000021329
4. Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases.
   L'Orphelin JM, Varey E, Khammari A, Dreno B, et al · · 2021 · cited 12× · PMID 34638410 · DOI 10.3390/cancers13194928
5. Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study.
   Vitek L, Goronflot T, Dutriaux C, Deleuze A, et al · · 2024 · cited 7× · PMID 39670438 · DOI 10.2340/actadv.v104.41297
6. Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas.
   Sanogo D, Levard R, Cassecuel J, Khammari A, et al · · 2026 · cited 2× · PMID 41277783 · DOI 10.1111/jdv.70136
7. Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.
   Tzoumpa S, Villette B, Granel-Brocard F, Dutriaux C, et al · · 2024 · cited 2× · PMID 39268924 · DOI 10.1080/1750743x.2024.2399498
8. Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis.
   Wang Y, Sun W, Wang B. · · 2025 · PMID 41170451 · DOI 10.3389/fonc.2025.1667282